WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/084141    International Application No.:    PCT/US2006/003861
Publication Date: 10.08.2006 International Filing Date: 03.02.2006
A61K 38/21 (2006.01), A61P 31/12 (2006.01), A61K 9/10 (2006.01), A61K 47/14 (2006.01), A61K 47/32 (2006.01), A61K 47/26 (2006.01), A61K 47/18 (2006.01)
Applicants: INTARCIA THERAPEUTICS, INC [US/US]; 2000 Powell Street, Suite 1640, Emeryville, Ca 94608 (US) (For All Designated States Except US).
AYER, Rupal A. [US/US]; (US) (For US Only).
DENNIS, Paula [--/US]; (US) (For US Only).
DESJARDIN, Michael A. [US/US]; (US) (For US Only).
LAM, Stanley [CA/US]; (US) (For US Only).
LIU, Kui [US/US]; (US) (For US Only).
MATSUURA, James E. [--/US]; (US) (For US Only).
NARAYANAN, Latha [US/US]; (US) (For US Only).
ROHLOFF, Catherine [US/US]; (US) (For US Only).
ZAMORA, Pauline C. [US/US]; (US) (For US Only)
Inventors: AYER, Rupal A.; (US).
DENNIS, Paula; (US).
DESJARDIN, Michael A.; (US).
LAM, Stanley; (US).
LIU, Kui; (US).
MATSUURA, James E.; (US).
ROHLOFF, Catherine; (US).
ZAMORA, Pauline C.; (US)
Agent: BECKER, Daniel M.; Dechert LLP, 1117 California Avenue, P.O. Box 10004, Palo Alto, CA 94303-0961 (US)
Priority Data:
60/650,226 03.02.2005 US
Abstract: front page image
(EN)A suspension formulation of interferon includes a non-aqueous, single-phase vehicle including at least one polymer and at least one solvent, the vehicle exhibiting viscous fluid characteristics, and an interferon contained in a particle formulation dispersed in the vehicle. The particle formulation includes a stabilizing component comprising one or more stabilizers selected from the group consisting of carbohydrates, antioxidants, and amino acids. The suspension formulation is characterized in that less than 10% of the interferon degrades over 3 months under an accelerated storage condition.
(FR)Une formulation en suspension d'interféron comprend un excipient non aqueux à simple phase comprenant au moins un polymère et au moins un solvant, l'excipient présentant des caractéristiques fluides visqueuses et un interféron contenu dans une formulation particulaire dispersée dans l'excipient. La formulation particulaire comprend un composant de stabilisation contenant un ou plusieurs stabilisateurs sélectionnés dans le groupe constitué d'hydrate de carbone, d'antioxydants et d'acides aminés. La formulation en suspension est caractérisée en ce que moins de 10 % de l'interféron se dégrade sur trois mois dans des conditions de stockage accéléré.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)